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ABSTRACT 
Purpose:  The aim of this study was to investigate the role of S-phase kinase associated protein 
(Skp2) in the development of nodal metastasis and to assess its influence on prognosis in stage I and 
II oral squamous cell carcinomas (OSCCs). 
Experimental Design:  Seventy-one patients affected by OSCC (stage I-II) were observed in the 
period ranging from March 2003 to December 2006. The research was performed using 
immunohistochemical and histopathological analysis. 
Results:  The overall survival rate was 89.6% at 3 years, 87% at 5 years and 80.7% at 10 years. 
Patients with vascular or perineural invasion showed no statistically significant survival difference 
when compared with the ones with no invasion. The tumour depth of invasion did not prove to be 
related to the metastatic potential. 
Nine of the seventeen patients with Skp2 positive nuclei (≥20%) developed nodal metastasis. 
Conversely, only 6 of the 54 patients with a nuclear positivity lower than 20% developed a 
laterocervical metastasis (P = 0.001). When comparing survival curves of Skp ≥ 20% and 
Skp2 < 20% OSCCs, no significant P value emerged from the statistical analysis. 
Conclusions:  This study is the first to report an important correlation between an Skp2 expression 
lower than 20% and the capability of the tumour not to develop nodal laterocervical metastases 
(P = 0.001). 
 
INTRODUCTION 
Nodal metastases represent the most important prognostic factor in the evaluation of oral squamous 
cell carcinomas (OSCCs): the 5-year survival rate decreases down to 50% in node-positive patients 
(N+), together with an increased risk of developing distant metastases (Regezi and Sciubba, 1989). 
Woolgar reports a 5-year survival equal to 81% for N0 (according to TNM staging system) patients, 
64% for patients presenting intra-nodal metastases and 21% for those with nodal metastasis and 
extra-capsular diffusion (Woolgaret al, 1999). 
Despite this, a unanimous consensus on laterocervical nodal treatment in stage I and II OSCC 
patients has not been reached yet. The literature presents diverse attempts at establishing factors 
related to probability of metastasis (perineural invasion, vascular invasion, inflammatory exudate, 
grading, pattern and depth of invasion) as an aid for the clinician when addressing the choice of 
whether a laterocervical dissection should be carried out in early stages of OSCCs (Garzino-Demo 
et al, 2006). 
In addition to these factors, several tissue and biological markers have been taken into consideration 
as possible indicators of tumour aggressiveness and predictors of the carcinogenic process and of 
the metastatic capability of the tumour itself (Brinkman and Wong, 2006). 
The S-phase kinase associated protein (Skp2) belongs to the F-box protein family (Fbps) and is able 
to break down p27 through ubiquitination. It also favours the transition from the G1 to the S phase 
of the cell cycle (Pagano et al, 1995; Fredersdorfet al,1997; Lodaet al, 1997; Porter et al,1997; 
Carranoet al, 1999; Tsvetkovet al, 1999). Furthermore, the forced expression of Skp2 in quiescent 
fibroblasts triggers DNA synthesis (Sutterlütyet al, 1999). An Skp2 overexpression has been 
noticed in diverse tumour types and is indicative of poor prognosis in patients affected by OSCC, 
gastric cancer, colon, ovarian, Gastrointestinal tract, pulmonary cancers and lymphomas 
(Woolgarand Scott, 1995; Hershkoet al, 2001; Kudo et al, 2001; Latreset al, 2001; Harada et al, 
2005a,b). These observations lead to the thought that Skp2 might have oncogenic properties. 
This work aims at identifying the relationship between both ipsilateral laterocervical and distant 
metastases in OSCCs and the semi-quantitative expression of Skp2 in cells found at the invasive 
tumour front in clinical and instrumental (TC and MR) N0 patients. Moreover, the correlation 
between overall survival of the examined sample and Skp2 expression was studied. The depth of 
tumour invasion (2 mm cut-off) was evaluated in relation to the metastatic ability of the tumour. 
MATERIALS AND METHODS 
Seventy-one patients affected by OSCC (stage I-II) came to our attention (Department of Maxillo-
Facial Surgery, University of Turin, Italy) and were involved into this study (Table 1). Forty-one of 
these (57.7%) were males and 30 females (42.3%). The mean age of subjects was 62 (range 24–82). 
Table 1.   Patients included in this study and their tumour stage, depth of invasion, follow-up, Skp2 
expression and 5-year survival  
Patient Stage Depth of invasion (mm) Follow-up 
Skp2 
expression Survival (5 years)
V.P. I <2 Free of disease 10% Alive 
M.I. I >2 Laterocervicalmetastasis 25% Alive 
L.E. I >2 Free of disease 5% Alive 
P.A. I >2 Free of disease 1% Deceased 
B.M.R. I <2 Free of disease Neg. Alive 
P.P. I >2 Free of disease 5% Deceased 
C.R. I <2 Free of disease 5% Alive 
A.R. I >2 Free of disease 5% Alive 
M.G. I <2 Free of disease 10% Deceased 
S.P. I <2 Free of disease Neg. Alive 
M.E. I >2 Free of disease Neg. Alive 
P.E. I >2 Laterocervicalmetastasis 15% Deceased 
L.F. I >2 Local recurrence 10% Alive 
R.I. I >2 Laterocervicalmetastasis 20% Alive 
C.G. II >2 Free of disease 5% Alive 
S.M. II >2 Free of disease 10% Alive 
K.M. I <2 Laterocervicalmetastasis 30% Alive 
G.G.C. I >2 Free of disease 10% Deceased 
G.L. I >2 Free of disease 10% Alive 
M.C. I <2 Free of disease 10% Alive 
V.F. I >2 Free of disease Neg Alive 
Table 1.   Patients included in this study and their tumour stage, depth of invasion, follow-up, Skp2 
expression and 5-year survival  
Patient Stage Depth of invasion (mm) Follow-up 
Skp2 
expression Survival (5 years)
M.A. II >2 Free of disease 2% Alive 
N.V. I >2 Free of disease 10% Alive 
G.R. I >2 Free of disease 10% Alive 
V.C.L. II >2 Free of disease 25% Alive 
R.R. II >2 Laterocervicalmetastasis 20% Deceased 
R.M. II >2 Local recurrence 10% Deceased 
C.A. II >2 Free of disease 30% Alive 
A.G. I >2 Laterocervicalmetastasis 10% Alive 
Z.M. I <2 Free of disease 5% Alive 
F.L. I <2 Free of disease 5% Alive 
M.I. I <2 Free of disease 10% Alive 
A.G. I >2 Laterocervicalmetastasis 25% Alive 
C.S. I >2 Free of disease 15% Alive 
G.M. II >2 Free of disease 5% Alive 
B.L. I <2 Local recurrence 5% Deceased 
M.Z.A. I >2 Free of disease 5% Alive 
G.G. II >2 Laterocervicalmetastasis Neg Alive 
B.S. I >2 Free of disease Neg Alive 
S.M. II >2 Free of disease 5% Alive 
P.F. II >2 Laterocervicalmetastasis 10% Alive 
S.B. I >2 Free of disease 40% Alive 
P.G. I <2 Free of disease Neg. Alive 
R.A.M. II >2 Laterocervicalmetastasis 25% Alive 
L.B.G. II >2 Free of disease Neg Alive 
F.S. II >2 Free of disease Neg Alive 
D.A. I >2 Laterocervicalmetastasis 30% Alive 
E.S. II >2 Free of disease 15% Alive 
V.G. II >2 Free of disease 15% Alive 
P.P. I <2 Laterocervicalmetastasis 10% Alive 
D.R.F. II >2 Free of disease neg Alive 
G.T. II >2 Laterocervicalmetastasis neg Deceased 
G.F. I <2 Free of disease 5% Alive 
B.M. I >2 Free of disease 15% Alive 
M.C. II >2 Lungmetastasis 30% Alive 
L.G. I >2 Free of disease 10% Alive 
A.P.A. I <2 Free of disease 25% Alive 
R.L. II >2 Free of disease 5% Alive 
S.F. I >2 Free of disease 2% Alive 
Table 1.   Patients included in this study and their tumour stage, depth of invasion, follow-up, Skp2 
expression and 5-year survival  
Patient Stage Depth of invasion (mm) Follow-up 
Skp2 
expression Survival (5 years)
P.S. I >2 Free of disease 15% Alive 
C.A. I <2 Free of disease 10% Alive 
M.N. I >2 Free of disease 20% Alive 
C.P. II >2 Free of disease 2% Deceased (other cause) 
B.G. I <2 Free of disease 5% Alive 
P.A. II >2 Free of disease 15% Alive 
G.T.T. I >2 Local recurrence 20% Deceased 
C.M. II >2 Local recurrence 40% Deceased 
A.C. II >2 Laterocervicalmetastasis 20% Deceased 
R.G. I <2 Free of disease 10% Alive 
F.L. I >2 Free of disease 30% Alive 
P.C. I <2 Free of disease 10% Alive 
Thirty-five of the 71 patients (49.3%) presented lesions localised to the buccal mucosa, whereas in 
36 cases (50.7%) the tongue margin and/or floor of the mouth were involved. 
Research was carried out onto the definitive anatomo-pathological findings (surgical pieces) which 
were evaluated through both a histopathological assessment (depth of invasion) and 
immunohistochemistry. The latter made use of a semiquantitative method (protein Skp-2 
expression). 
The tumour depth of invasion (2 mm cut-off) and its relationship with the presence of a 
laterocervical nodal metastasis and/or a distant metastasis was also assessed. 
Data were then correlated with the presence of ipsilateral nodal metastasis, distant metastasis and 
with the cumulative survival of the examined sample with a minimum 3-year follow-up. 
 
IMMUNOHISTOCHEMISTRY 
The immunohistochemical evaluation was carried out onto 4-micron thick specimens, each obtained 
by fixation of the pieces into 4% formalin and subsequent paraffin inclusion. Sections were then 
deparaffined in xylol and hydrated through the passage in a decreasing alcohol series. The activity 
of endogenous peroxidases was subsequently inhibited by using 0.3% H2O2 for 15 min. To intensify 
the signal, antigen demasking was carried out by means of two microwave cycles (15 min each), 
adopting a citrate buffer (pH 6.2). The monoclonal Mouse anti-Skp2 antibody (clone 2C8D9, 
Zymed) was adopted to assess the expression of Skp2. Sections were then incubated with the above-
mentioned antibody at 1:100 dilution for 60 min at room temperature. The avidin-biotin-peroxidase 
complex, which uses diaminobenzidine (DAB) as chromogene, was adopted. After the process of 
oxidation is completed, DAB precipitates where the antigen-antibody bond has taken place. Normal 
mouse serum containing immunoglobulins at a concentration similar to that of the primary antibody 
was adopted as a negative control. 
Immunostained sections were then evaluated by three independent observers. None of them had any 
knowledge of the clinical/histological diagnosis. For each examined specimen section, the mean 
percentage of cells which resulted to be positive at the invasive front was evaluated. The percentage 
of positively-stained cells in each specimen was estimated by counting the number of cells per area 
from at least three different areas. The nuclear positivity for the antibody was considered to be 
specific. On the basis of previous works found in the literature, this study took into account a cut-
off value of 20% to sub-divide samples into those with a high and those with a low Skp2 protein 
expression (Figures 1 and 2) (Gstaigeret al, 2001; Hershkoet al, 2001; Harada et al, 2005a,b). 
STATISTICAL ANALYSIS 
The statistical analysis was carried out by means of Kaplan–Meier survival curves and considering 
overall survival, stage and Skp2 expression separately. The statistical significance was assessed 
with log-rank tests. 
Chi-square and Fisher’s exact tests were adopted to carry out the univaried analysis of metastatic 
capability in relation with both Skp2 expression and depth of invasion. 
The day of surgery was considered as time zero. Patients who remained alive were included in the 
group of ‘subjects at risk of death due to disease’ up to the last follow-up. This is why survival 
curves change only when the subject deceases. 
Survival curves have been estimated to be realistically compatible with the actual survival curves. 
The statistical analysis was carried out using the STATA 8 software Science Plus Group, 
Groningen, Netherlands. 
RESULTS 
The overall patient survival was evaluated by means of Kaplan–Meier algorithms, which revealed 
3, 5 and 10-year overall rates equal to 89.6%, 87% and 80.7%, respectively. 
When analysing survival in relation to tumour stage, the results showed a non-statistically 
significant difference with a Chi square value of 0.69 and P = 0.42 (Figure 3). 
 
Figure 3.   Survival curves related to tumour stage. This analysis shows no statistically significant 
difference in survival when comparing Stage I and Stage II tumours 
Correlation between tumour depth of invasion and both nodal and distant metastases 
Fifty-two of the 71 patients presented a depth of invasion ≥2 mm. Of these, 13 developed a 
metastasis. The results reported in Figure 1 are not correlated in a statistically significant fashion 
(P = 0.186). 
Correlation between Skp2 expression and both nodal and distant metastases 
Seventeen of the 71 patients considered in this study showed Skp2 positive nuclei (≥20%). Of these 
seventeen, nine developed a laterocervical metastasis in time. Conversely, only 6 of the 54 patients 
with a nuclear positivity lower than 20% developed a laterocervical metastasis (Table 2). 
Table 2.   Correlation between tumour depth of invasion and both nodal and distant metastases 
  <2 mm ≥2 mm Total 
No Metastasis 17 39 56 
Metastasis 2 13 15 
Total 19 52 71 
Only one Skp2-positive patient eventually resulted to be affected by a distant metastasis (lung). 
Data shown in Table 3 were evaluated by means of Chi-square test, obtaining a value of 13.5768. 
The probability was equal to 0.000. Fisher’s exact test was carried out for this value with P = 0.001. 
Table 3.   Correlation between Skp2 expression and both nodal and distant metastases 
  skp2 < 20% skp2 ≥ 20% Total 
No metastasis 48 8 56 
Metastasis 6 9 15 
Total 54 17 71 
Correlation between Skp2 expression and survival curves 
The statistical analysis carried out by means of survival curves highlighted a non-significant P 
value. Nevertheless, all deaths in patients who presented Skp2 values ≥20% took place within 
3 years from surgery. In contrast with this, deaths in subjects with Skp2 < 20% were observed to be 
equally distributed over a 9-year time lapse. 
One patient only died as a consequence of unrelated circumstances, whereas 12 patients died 
because of disease (Figure 4). Of these 12, four patients showed an Skp2 positivity≥20% and the 
remaining eight subjects presented Skp2 values <20%.Such difference proved not to be statistically 
significant with Chi-Square = 0.87 and P = 0.35. 
 
Figure 4.   Survival curves in relation to Skp2 expression. This analysis shows no statistically 
significant difference in survival rates between patients showing Skp2 ≥ 20% and those showing 
Skp2 < 20% 
DISCUSSION 
Depth of invasion is believed to be one of the most important prognostic factors in early stages of 
oral squamous cell carcinoma (Woolgar and Scott, 1995; Po Wing Yuen et al, 2002; O-
Charoenratet al, 2003; Alkureishiet al, 2008; Shah and Gil, 2009). A recent review of the literature 
(Kudo et al, 2005) pointed out that when considering depth of invasion, the cut-off value adopted 
by different studies ranges from 1.5 mm (Mohit-Tabatabaiet al,1986) to 10 mm (Al Rajhiet al, 
2000). At present, there is neither agreed nor unambiguous cut-off value yet (Penteneroet al, 2005; 
O'Brien et al, 2003). This study adopted a 2 mm cutoff, the rationale behind this choice being that 
of distinguishing the metastatic potential of a microinvasive versus an invasive carcinoma 
(Crissman and Zarbo, 1989). 
Of the 71 patients who took part in the study, 52 showed a depth of invasion >2 mm. Thirteen of 
these developed a laterocervical metastasis and such a correlation resulted not to be statistically 
significant (P = 0.186). 
However, the present work aimed at focusing on Skp2 analysis mainly. When considering oral 
squamous cell carcinomas, as a result of the emerging need to improve therapeutic strategies in 
early stages (T1-T2), the identification of a biomarker whose expression might be correlated to 
prognosis and metastatic potential of the tumour itself becomes increasingly important. The 
determination of such a marker by means of immunohistochemistry would be the most convenient 
and valid method of risk stratification of patients. 
The applications of the oncoprotein Skp2 have recently become of remarkable interest when 
evaluating prognosis in diverse human carcinomas (Hershko, 2008). Its overexpression has been 
observed in different malignant tumours, including OSCCs (Gstaigeret al, 2001; Hershkoet al, 
2001; Kudo et al, 2001; Latreset al, 2001; Masuda et al, 2002), although the mechanism that leads 
to such an overexpression remains unknown (Lin et al, 2006). Skp2 belongs to the F box protein 
family and it performs its oncogenic activity by modulating the ubiquitination and degradation of 
p27 (Pagano et al,1995; Fredersdorfet al,1997; Lodaet al,1997; Porter et al,1997; 
Carranoet al,1999; Tsvetkovet al,1999). The conversion of healthy cells into tumoural cells takes 
place through a multi-step process that is associated with an accumulation of genetic modifications 
which involves also oncogenes and tumour suppressor genes (Marx,1989). Some suggest that 
proliferation and the subsequent tumour progression might actually be caused by anomalies of 
diverse positive and negative cell cycle regulators (Hunter and Pines, 1994; Sherr, 1996). 
Progression of the cell cycle is positively regulated by multiple cyclins and cyclin-dependent 
kinases (CDKs). The cyclin/CDK complexes are activated by means of phosphorylation which is 
carried out by CDK activating kinases (CAK) and that, in turn, are negatively regulated by diverse 
CDK inhibitors (CDIs) (Toyoshima and Hunter, 1994; Sherr, 1996). The expression of cyclins, 
CDKs and CDIs, which is finely coordinated in non-pathological conditions, is often deregulated in 
tumours (Carracedoet al, 2008). The role played by p27 is that of a negative regulator of G0/G1 
phase and a low expression of this protein is associated with disease progression (Hunter and Pines, 
1994; Toyoshima and Hunter, 1994). Diverse studies report a down-regulation of p27 in OSCCs 
(Kudoet al,1998; Fujiedaet al,1999; Minetaet al,1999; Singerland and Pagano, 2000; Shintaniet al, 
2002; Choi et al, 2003) accompanied by an overexpression of Skp2 (Gstaigeret al, 2001; Kudo 
et al, 2001; Shintaniet al, 2003). Fewer studies have, however, investigated the cell migration upon 
which the metastatic capability of the tumour depends. A reduced p27 expression was found 
approximately in 87% of OSCCs and it is strongly associated with early tumour invasion, cell 
proliferation and metastatic potential (Kudo et al,1998; Minetaet al,1999; Shoelchet al,1999; 
Bloom and Pagano, 2003; Choi et al, 2003). The overexpression of p27 in healthy epithelia is well 
documented and known, whereas the oncoprotein Skp2 is poorly expressed. The reduction of p27 
levels and the simultaneous increase of Skp2, which are thus inversely correlated, are indeed 
observable in epithelial dysplasia, OSCCs and early sub-epithelial tumour invasion (Jordan et al, 
1998; Kudo et al, 2000, 2001; Gstaigeret al, 2001; Hershkoet al, 2001; Latreset al, 2001; Masuda 
et al, 2002). Kudo hypothesised that the down-regulation of p27 may play a major role in the 
tumour invasion and metastasis processes mediated by the loss of cell-adhesion mechanisms (Kudo 
et al, 2000). However, the relation linking the down-regulation of p27 and metastasis remains 
unknown (St Croix et al, 1996). 
In addition to this, a study conducted by Harada et al (2005a, 2005b) revealed that an Skp2 down-
regulation actually induces apoptosis in OSSCs tumoural cells; furthermore, forcing the expression 
of Skp2 in quiescent fibroblasts induces DNA synthesis (Gstaigeret al, 2001). These results suggest 
that Skp2 possesses oncogenic properties. 
The purpose of the present work was that of analysing the expression of Skp2 (20% cut-off) 
(Gstaigeret al, 2001; Harada et al, 2005a,b) and to correlate its tumoural levels with both the 
appearance of a regional nodal metastasis and prognosis in stage I and II OSCCs. Furthermore, the 
overall survival of the considered sample with respect to Skp2 expression was evaluated. Two 
different localizations of nodal spread were considered, so as to better evaluate the potency of Skp2 
and to analyse its metastatic potential. 
The overall survival of the sample of patients considered in this study was evaluated using Kaplan-
Meier curves and data showed overall survival rates equal to 89.6%, 87% and 80.7% at 3, 5 and 
10 years, respectively. The survival rates for early oral squamous cell carcinomas at 5 years which 
are reported in the literature range between 70 and 90% for tongue cancer and between 66 and 78% 
for carcinoma of the buccal mucosa (Diaz et al, 2003; Lin et al, 2006; Shaw et al, 2009). 
The statistical analysis correlating survival curves and Skp2 expression that was carried out on our 
study sample showed a non-significant P value. However, an important element emerges from the 
present data: patients who presented Skp2 values greater than 20% deceased within 3 years from 
surgery. The previous studies demonstrated a strong correlation between Skp2 overexpression, 
metastatic capability of the tumour and a decrease in overall survival (Harada et al, 2005a,b; 
Carracedoet al, 2008). 
Interesting results were obtained when analysing the relationship between Skp2 expression and both 
nodal and distant metastases. From our data one can gather that in those cases where Skp2 ≥ 20%, 
the cases of metastases (9 over 17) and no metastases (8 over 17) are similar in number. The 
situation changes when considering patients who presented Skp2 < 20%, in which case a strict 
interrelation between the absence of metastases and such an Skp2 expression is noticeable. In fact, 
of the 54 patients with Skp2 < 20%, 48 did not develop any nodal laterocervical metastasis, while 
seven of them did. Such a correlation resulted statistically significant with P = 0.001. 
Apparently, just as literature reports for other tumours, high Skp2 levels play a predictive role also 
in OSCCs when considering the potential of the tumour to develop nodal metastases. This study is 
the first to report an important correlation between an Skp2 expression lower than 20% and the 
capability of the tumour not to develop nodal laterocervical metastases (P = 0.001). 
CONCLUSIONS 
The understanding and analysis of the expression of Skp2 have interested many studies in the last 
few years. However, further research is needed to better comprehend its action mechanisms and its 
predictive value for the development of metastases in oral squamous cell carcinoma. On the other 
hand, one should bear in mind the importance of deepening the knowledge on bio-tissue markers 
which could predict the metastatic behaviour of tumours. This could severely improve the 
therapeutic approach to OSCCs and possibly increase survival rates at 5 years of stage I-II 
carcinomas which is, at present, reported to range between 70 and 80%. 
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